Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 8.73B |
| Revenue (ttm) | 834.53M |
| Net Income (ttm) | 73.86M |
| Shares Out | 31.50M |
| EPS (ttm) | 2.34 |
| PE Ratio | 118.32 |
| Forward PE | 62.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 99,581 |
| Average Volume | 132,706 |
| Open | 277.80 |
| Previous Close | 277.20 |
| Day's Range | 269.60 - 280.20 |
| 52-Week Range | 160.00 - 338.00 |
| Beta | 1.40 |
| RSI | 60.22 |
| Earnings Date | Apr 24, 2026 |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermi... [Read more]
Financial Performance
In 2025, Xvivo Perfusion AB's revenue was 812.17 million, a decrease of -1.25% compared to the previous year's 822.42 million. Earnings were 25.16 million, a decrease of -85.39%.
Financial StatementsNews
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV): The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusio...
Xvivo Perfusion AB (XVIPF) Q1 2026 Earnings Call Highlights: Strong Organic Growth and Positive ...
Xvivo Perfusion AB (XVIPF) Q1 2026 Earnings Call Highlights: Strong Organic Growth and Positive Cash Flow
Q1 2026 Xvivo Perfusion AB Earnings Call Transcript
Q1 2026 Xvivo Perfusion AB Earnings Call Transcript
Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ)
GOTHENBURG, SE / ACCESS Newswire / March 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice of th...
The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Ahead of the Annual General Meeting to be held on 27 April 2026, the Nomination Committee p...